New drug combo aims to tackle Hard-to-Treat cancers
NCT ID NCT03919292
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neratinib and divalproex sodium (valproate)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors, especially those with RAS mutations, which are hard to treat.
What could go wrong
This is an early phase 1/2 trial with a small number of participants (83). The drug combo may not work or could cause serious side effects. Success is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, 23298, United States